Highest Score

Ranked by analysis score
Ranks this page's recent reports by score.
Kontoor Brands, Inc.
KTB·Consumer Discretionary
A ★★★★Buy
Current$84.90
Target$98.05
Return+15.5%
Aug 18, 2026

Kontoor Brands is aggressively upgrading its margin and growth profile by swapping legacy denim for premium outdoor apparel, executing a massive $400M share buyback that makes the stock a screaming value, though investors must monitor execution risks surrounding stranded corporate costs and escalating U.S. import tariffs.

Score
93
Halozyme Therapeutics, Inc.
HALO·Healthcare
A ★★★★Buy
Current$103.12
Target$135.00
Return+30.9%
Aug 12, 2026

Halozyme is a fundamentally flawless, hyper-profitable royalty machine trading at a deeply distressed valuation, though investors must aggressively navigate the binary, high-stakes legal battle surrounding its core patents against emerging rival Alteogen.

Score
93
NNN REIT, Inc.
NNN·Real Estate
A ★★★★Buy
Current$46.98
Target$53.55
Return+14.0%
Aug 12, 2026

NNN REIT offers a highly durable, cycle-tested dividend stream backed by a granular portfolio of freestanding retail properties, presenting a compelling income opportunity at current valuations despite macroeconomic interest rate headwinds.

Score
93
Globus Medical, Inc.
GMED·Healthcare
A ★★★★Buy
Current$86.15
Target$104.08
Return+20.8%
Aug 11, 2026

Globus Medical leverages its peerless Excelsius robotic ecosystem to drive sticky, high-margin implant volume and massive cash generation, trading at a deeply unjustified discount despite its flawless balance sheet and successful NuVasive integration.

Score
93
Elanco Animal Health Incorporated
ELAN·Healthcare
A ★★★★Buy
Current$22.12
Target$30.00
Return+35.6%
Aug 11, 2026

Elanco is a rapidly deleveraging, deeply undervalued animal health powerhouse driving a massive margin expansion cycle via its new blockbuster dermatology and livestock portfolio, though investors must closely monitor veterinarian adoption of Zenrelia amidst its highly restrictive FDA vaccine warning.

Score
93
Realty Income Corporation
O·Real Estate
A ★★★★Buy
Current$62.51
Target$68.90
Return+10.2%
Aug 9, 2026

Realty Income's A-rated balance sheet supports monthly dividends at a rate-driven discount, while private-capital ventures aid per-share growth; retail tenant restructurings create near-term uncertainty.

Score
93
Broadridge Financial Solutions, Inc.
BR·Technology
A ★★★★Buy
Current$168.41
Target$208.00
Return+23.5%
Aug 5, 2026

Broadridge remains an entrenched, highly profitable tollbooth in financial infrastructure, successfully leveraging its proxy monopoly to fund growth in AI and tokenization, making its recent 16x forward multiple an attractive entry point despite long-term disruption risks.

Score
93
Telefônica Brasil S.A.
VIV·Communication Services
A ★★★★Buy
Current$13.41
Target$15.47
Return+15.3%
Jul 30, 2026

Telefônica Brasil merges a highly defensive mobile triopoly moat with robust FTTH convergence to deliver massive, 100%-payout cash flows, presenting an elite income asset that is structurally mispriced due to transient Brazilian macroeconomic fears.

Score
93
Northern Oil and Gas, Inc.
NOG·Energy
A ★★★★Buy
Current$27.34
Target$29.88
Return+9.3%
Aug 26, 2026

Northern Oil and Gas is the undisputed, hyper-efficient non-operating consolidator of US shale, generating massive cash flow at a deeply distressed valuation, though investors must continuously monitor the vulnerability of its aggressive debt-funded acquisition pipeline.

Score
92
Digi International Inc.
DGII·Technology
A ★★★★Buy
Current$74.91
Target$93.90
Return+25.4%
Aug 25, 2026

Digi International is moving from cyclical hardware to a sticky, high-margin software ecosystem at a steep discount to software peers, though investors must monitor the balance sheet leverage built up through its aggressive M&A strategy.

Score
92
Baytex Energy Corp.
BTE·Energy
A ★★★★Buy
Current$4.81
Target$6.88
Return+43.0%
Aug 23, 2026

Baytex Energy is a uniquely derisked, cash-gushing oil producer utilizing a pristine balance sheet to aggressively cannibalize its own shares at bargain multiples, though investors must remain hyper-vigilant regarding extreme volatility in global crude benchmarks and heavy oil differentials.

Score
92
Golub Capital BDC, Inc.
GBDC·Financials
A ★★★★Buy
Current$13.26
Target$14.25
Return+7.5%
Aug 22, 2026

Golub Capital BDC offers elite, heavily discounted exposure to a massive 92% first-lien private credit portfolio fortified by a new shareholder-friendly fee structure, though investors must accept moderate yield compression as the Federal Reserve initiates its long-awaited interest rate cutting cycle.

Score
92